These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27818254)

  • 1. Defining drug response for stratified medicine.
    Lonergan M; Senn SJ; McNamee C; Daly AK; Sutton R; Hattersley A; Pearson E; Pirmohamed M
    Drug Discov Today; 2017 Jan; 22(1):173-179. PubMed ID: 27818254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].
    Müller-Berghaus J; Volkers P; Scherer J; Cichutek K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1538-44. PubMed ID: 24170083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine, pharmacogenomic and companion biomarker.
    Manceau H; Amrani K; Peoc'h K
    Ann Biol Clin (Paris); 2017 Dec; 75(6):631-636. PubMed ID: 29192598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The relevance of biomarkers for personalised medicine].
    Großhennig A; Benda N; Koch A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1480-8. PubMed ID: 24084852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Laboratory monitoring of the efficacy and safety of anticoagulants].
    Dankovtseva EN; Zotova IV; Zateĭshchikov DA
    Kardiologiia; 2014; 54(5):88-96. PubMed ID: 25177894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving drug safety by locating genetic markers for hypersensitivity reactions.
    Ronaldson KJ; McNeil JJ
    Med J Aust; 2009 Jun; 190(11):641-3. PubMed ID: 19485844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic biomarkers: new tools in current and future drug therapy.
    Sim SC; Ingelman-Sundberg M
    Trends Pharmacol Sci; 2011 Feb; 32(2):72-81. PubMed ID: 21185092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.
    Pirmohamed M
    Annu Rev Genomics Hum Genet; 2014; 15():349-70. PubMed ID: 24898040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mathematics of drug dose individualization should be built with random-effects linear models.
    Diaz FJ; de Leon J
    Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics, pharmacogenomics, and individualized medicine.
    Ma Q; Lu AY
    Pharmacol Rev; 2011 Jun; 63(2):437-59. PubMed ID: 21436344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].
    Stingl JC; Just KS; Kaumanns K; Schurig-Urbaniak M; Scholl C; von Mallek D; Brockmöller J
    Internist (Berl); 2016 Mar; 57(3):289-97. PubMed ID: 26830424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine in children with asthma.
    Pijnenburg MW; Szefler S
    Paediatr Respir Rev; 2015 Mar; 16(2):101-7. PubMed ID: 25458797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
    Holford NH; Buclin T
    Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
    [No Abstract]   [Full Text] [Related]  

  • 16. [Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
    Kaniwa N
    Yakugaku Zasshi; 2015; 135(5):671-9. PubMed ID: 25948300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic Markers of Drug Efficacy and Toxicity.
    Yip VL; Hawcutt DB; Pirmohamed M
    Clin Pharmacol Ther; 2015 Jul; 98(1):61-70. PubMed ID: 25870137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy.
    Becker RC
    J Thromb Thrombolysis; 2008 Jun; 25(3):300-2. PubMed ID: 18470653
    [No Abstract]   [Full Text] [Related]  

  • 20. "No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!
    Milano G; Innocenti F; Lacarelle B; Ciccolini J
    Crit Rev Oncol Hematol; 2018 Jul; 127():1-5. PubMed ID: 29891106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.